HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

July 14, 2026 updated by: Newsoara Biopharma Co., Ltd.

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Oral HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are:

Does drug HPP737 improve psoriasis severity compared to a placebo at Week 16, as measured by the proportion of patients achieving a significant reduction in the Psoriasis Area and Severity Index (PASI) score? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to a placebo (a look-alike substance that contains no drug) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. Participants will:

Take drug HPP737 or a placebo orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools, including the Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), and Body Surface Area (BSA) Eligible participants are adults aged 18 years and older with a confirmed diagnosis of chronic plaque psoriasis for at least 6 months and moderate-to-severe disease at screening.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

HPP737-Psoriasis-301 is a phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy and safety of oral HPP737 in adult patients with moderate-to-severe plaque psoriasis. The study is sponsored by Newsoara Biopharma Co., Ltd. The trial involves approximately 504 patients across multiple centers nationwide.

HPP737 is a novel, potent, orally administered, and selective phosphodiesterase type 4 (PDE4) inhibitor. PDE4 is a validated therapeutic target for inflammatory diseases including psoriasis. By inhibiting PDE4, HPP737 raises intracellular cyclic adenosine monophosphate (cAMP) levels, thereby exerting broad anti-inflammatory effects. Preclinical and clinical data have demonstrated that HPP737 potently inhibits interleukin-23 (IL-23) and tumor necrosis factor alpha (TNF-α) production both in vitro and in vivo. Notably, HPP737 has shown a favorable safety and tolerability profile in phase I studies, with no dose-limiting gastrointestinal side effects-such as nausea, vomiting, or diarrhea-commonly associated with other PDE4 inhibitors.

This is a randomized, double-blind, placebo-controlled, parallel-group trial. Eligible patients are adults aged ≥18 years with a confirmed diagnosis of stable chronic plaque psoriasis for ≥6 months and moderate-to-severe disease at screening, defined by Psoriasis Area and Severity Index (PASI) score ≥12, static Physician's Global Assessment (sPGA) score ≥3, and body surface area (BSA) involvement ≥10%. Patients are randomized in a 1:1:1 ratio to one of three treatment arms: HPP737 10 mg once daily, HPP737 20 mg once daily, or placebo.

The total treatment duration is 52 weeks, divided into two phases:

Core Phase (Weeks 0-16): Patients receive double-blind treatment with HPP737 10 mg, HPP737 20 mg, or placebo.

Extension Phase (Weeks 16-52): Patients who complete the core phase enter the extension phase. Those originally assigned to placebo are switched to HPP737 20 mg; patients in the HPP737 10 mg and 20 mg groups continue on their assigned doses without adjustment.

The primary objective is to evaluate the efficacy of HPP737 compared with placebo at Week 16 in patients with moderate-to-severe plaque psoriasis. Secondary objectives include: (1) evaluation of additional efficacy characteristics of HPP737 versus placebo; (2) assessment of the safety of HPP737 in patients with moderate-to-severe chronic plaque psoriasis; and (3) evaluation of population pharmacokinetic (PPK) characteristics of HPP737 in this patient population.

The study is conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
515

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Beijing, China
        • Beijing Friendship Hospital, Capital Medical University
      • Beijing, China
        • Peking University People's Hospital
      • Beijing, China
        • Beijing Tongren Hospital, Capital Medical University
      • Bengbu, China
        • The First Affiliated Hospital of Bengbu Medical College
      • Cangzhou, China
        • Cangzhou People's Hospital
      • Changchun, China
        • The Second Hospital of Jilin University
      • Changsha, China
        • The Second Xiangya Hospital of Central South University
      • Changsha, China
        • The Third Xiangya Hospital of Central South University
      • Changsha, China
        • Xiangya Hospital, Central South University
      • Chengde, China
        • Affiliated Hospital of Chengde Medical College
      • Chengdu, China
        • Chengdu Second People's Hospital
      • Dongguan, China
        • Dongguan First People's Hospital
      • Dongying, China
        • Shengli Oilfield Central Hospital
      • Gannan, China
        • The First Affiliated Hospital of Gannan Medical University
      • Guangzhou, China
        • Guangdong Provincial People's Hospital
      • Guangzhou, China
        • The Sixth Affiliated Hospital of Sun Yat-sen University
      • Guangzhou, China
        • The Third Affiliated Hospital of Sun Yat-sen University
      • Guangzhou, China
        • Dermatology Hospital, Southern Medical University
      • Guilin, China
        • Affiliated Hospital of Guilin Medical University
      • Guiyang, China
        • Shandong Provincial Hospital of Dermatology
      • Hangzhou, China
        • Zhejiang Provincial People's Hospital
      • Hangzhou, China
        • Hangzhou First People's Hospital
      • Hangzhou, China
        • Hangzhou Third People's Hospital
      • Harbin, China
        • The Second Affiliated Hospital of Harbin Medical University
      • Jiaxing, China
        • Jiaxing First Hospital
      • Jinan, China
        • Shandong Provincial Hospital
      • Jinan, China
        • Jinan Central Hospital
      • Jinan, China
        • Shandong Provincial Hospital of Dermatology
      • Kunming, China
        • The First Affiliated Hospital of Kunming Medical University
      • Lianyungang, China
        • Lianyungang First People's Hospital
      • Nanchang, China
        • Jiangxi Provincial Dermatology Hospital
      • Nanyang, China
        • Nanyang Central Hospital
      • Nanyang, China
        • Nanyang First People's Hospital
      • Shanghai, China
        • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM
      • Shanghai, China
        • Shanghai Skin Disease Hospital
      • Shijiazhuang, China
        • The First Hospital of Hebei Medical University
      • Shiyan, China
        • Shiyan People's Hospital
      • Suining, China
        • Suining Central Hospital
      • Tianjin, China
        • Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine
      • Wuhan, China
        • Wuhan First Hospital
      • Wuhu, China
        • Yijishan Hospital of Wannan Medical College
      • Wuxi, China
        • Wuxi Second People's Hospital
      • Wuxi, China
        • Jiangyin Hospital of Traditional Chinese Medicine
      • Xi'an, China
        • The First Affiliated Hospital of Xi'an Jiaotong University
      • Xiamen, China
        • The Second Affiliated Hospital of Xiamen Medical College
      • Xianyang, China
        • Xianyang Hospital of Yan'an University
      • Yancheng, China
        • Yancheng First People's Hospital
      • Yantai, China
        • Yantai Yuhuangding Hospital
      • Yinchuan, China
        • General Hospital of Ningxia Medical University
      • Zhenjiang, China
        • Affiliated Hospital of Jiangsu University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Subjects voluntarily sign the informed consent form before initiation of any study-related procedures, are able to communicate effectively with investigators, and understand and comply with all requirements of this study;
  • Age at signing informed consent: age ≥18 years, regardless of gender;
  • Diagnosed with a history of chronic plaque psoriasis (Psoriasis vulgaris) and disease stability for ≥6 months prior to screening;
  • Diagnosed with moderate to severe plaque psoriasis (Psoriasis vulgaris), and at screening meets the following requirements: 1) PASI (Psoriasis Area and Severity Index) score ≥ 12; and 2) Static Physician Global Assessment (sPGA) score ≥ 3; and 3) Body Surface Area (BSA) involvement ≥ 10%;
  • Body Mass Index (BMI): 18 kg/m2 ≤ BMI ≤ 35 kg/m2

Exclusion Criteria:

  • At screening, diagnosis of psoriasis types other than chronic plaque psoriasis (Psoriasis vulgaris), e.g., pustular psoriasis (Psoriasis pustulosa), erythrodermic psoriasis (Psoriasis erythrodermica), and guttate psoriasis (Psoriasis guttata);
  • Patients with drug-induced psoriasis (including but not limited to new-onset or exacerbation of psoriasis caused by β-blockers [beta-blockers], calcium channel inhibitors [calcium channel blockers], or lithium preparations [lithium salts]);
  • Subjects have other skin diseases that may interfere with clinical assessment (e.g., bacterial, fungal, or viral skin infections, seborrheic dermatitis), chronic diarrhea, severe digestive diseases (such as active gastric ulcer, gastrointestinal tract disorders), or history of inflammatory bowel disease (Crohn's disease, ulcerative colitis), or other active autoimmune inflammatory diseases (mixed connective tissue disease, idiopathic inflammatory myopathy); Note: Chronic diarrhea is defined as disease course >4 weeks, or recurrent diarrhea in a 2-4 week interval. Diarrhea refers to defecation significantly exceeding usual frequency (>3 times/day), stool consistency is loose, water content (>85%), and stool may contain mucus, pus, blood, or undigested food.
  • History of congenital or acquired immunodeficiency;
  • Severe infection or systemic infection within 4 weeks prior to randomization requiring oral and/or intravenous antimicrobial treatment, or hospitalization due to infection;
  • At screening, subject's history, symptoms, and examination results indicate active tuberculosis;
  • History of moderate-to-severe heart failure (New York Heart Association [NYHA] functional classification ≥ Class 3), or occurrence of cardiovascular or cerebrovascular events or severe events within 3 months prior to randomization, such that investigators consider these subjects unsuitable for participation in this clinical trial;
  • History of malignancy in any organ system within 5 years prior to randomization, except for malignancies with low risk of metastasis and mortality, such as adequately treated carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin;
  • Subjects with a history of depression and/or, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) during the screening and baseline period, with ideation or any behavior (see Appendix 6). Subjects who answer "yes" to any question on the C-SSRS questionnaire, or those deemed at risk by the investigator's clinical judgment, will be excluded;
  • Presence of clinically significant, progressive, or uncontrolled disease during the screening period, including but not limited to respiratory, cardiovascular, endocrine, hematologic, skeletal, or neurologic systems, as assessed by the investigator to pose unacceptable risk for participation or interfere with data interpretation;
  • Prior to screening, use of the following psoriasis treatment modalities/drugs: 1) Received topical treatment for psoriasis within 2 weeks prior to randomization, such as glucocorticoids, vitamin D3 derivatives, retinoids, etc.; however, the subject is permitted to use the following topical treatments: non-medicated shampoos and emollients (i.e., those not containing glucocorticoids or vitamin D3 derivatives); Received phototherapy/photochemotherapy (including but not limited to psoralen plus ultraviolet A [PUVA] therapy, ultraviolet B [UVB]), or non-biological systemic therapy (including but not limited to systemic glucocorticoids, leflunomide, cyclophosphamide, azathioprine, methotrexate, cyclosporine, retinoids, mycophenolate mofetil, traditional Chinese medicine for the treatment of psoriasis, or other small-molecule targeted agents for the treatment of psoriasis) within 4 weeks prior to randomization; Tumor necrosis factor-alpha (TNF-α) antagonist: (1) The patient has used at least one TNF-α antagonist within the specified time period prior to randomization (for example, adalimumab, infliximab, golimumab, etanercept, or certolizumab pegol within 12 weeks prior to randomization); (2) or the patient has used two or more TNF-α antagonists prior to randomization; 4) Used other biologic agents within 24 weeks prior to randomization, including but not limited to anti-interleukin-17 (anti-IL-17) inhibitors, anti-interleukin-23 (anti-IL-23) inhibitors, anti-interleukin-12/interleukin-23 (anti-IL-12/23) inhibitors, and related agents;
  • Receipt of live attenuated vaccines within 12 weeks prior to randomization, or planned vaccination with live attenuated vaccines during the study period;
  • Subjects who have previously used other PDE4 inhibitors (such as apremilast, Hemay005, etc.);

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: HPP737 10 mg
Specification: 10 mg Dosage and Administration: Two capsules (one with 10 mg HPP737 and one with 10 mg placebo) are administered orally once daily for a total duration of 52 weeks.
Drug: HPP737
HPP737 capsule for oral administration
Experimental: HPP737 20 mg
Specification: 10 mg Dosage and Administration: Two capsules (two with 10 mg HPP737) are administered orally once daily for a total duration of 52 weeks.
Drug: HPP737
HPP737 capsule for oral administration
Placebo Comparator: Placebo (cross over to HPP737 20mg at Week 17)

Specification: 10 mg Administration and dosage: Two capsules (two with 10 mg placebo) are administered orally once daily for a total duration of 16 weeks.

Then patients will be crossed over to receive HPP737 20 mg once daily starting at Week 17 and continuing through Week 52.
Drug: HPP737
HPP737 capsule for oral administration
Drug: Placebo matching HPP737
Placebo capsules matching HPP737 for oral administration
Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
To evaluate the proportion of subjects who achieve PASI 75 (a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score ）from baseline to Week 16
Time Frame: From enrollment to end of treatment at 16 weeks
From enrollment to end of treatment at 16 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
To evaluate the proportion of subjects who achieve a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) and who have a reduction of ≥2 points from baseline to Week 16.
Time Frame: From enrollment to end of treatment at 16 weeks
From enrollment to end of treatment at 16 weeks
To evaluate the proportion of subjects who achieve PASI 75 (a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score ）from baseline to Week 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
Time Frame: From enrollment to end of treatment at 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks
From enrollment to end of treatment at 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks
To evaluate the proportion of subjects who achieve PASI 50 (a ≥ 50% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score ）at Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
Time Frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
To evaluate the proportion of subjects who achieve PASI 90 (a ≥ 90% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score ）from baseline to Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
Time Frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
To evaluate the proportion of subjects who achieve PASI 100 (a ≥ 100% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score ）from baseline to Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
Time Frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
To evaluate the change from baseline in PASI(Psoriasis Area and Severity Index) score and the percent change from baseline at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
Time Frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
To evaluate the proportion of subjects who achieve a sPGA score of 0 (clear) or 1 (almost clear) and who have a reduction of ≥2 points from baseline at Week 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
Time Frame: From enrollment to end of treatment at 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
From enrollment to end of treatment at 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
To evaluate the change from baseline in BSA and the percent change from baseline at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
Time Frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
To evaluate the change from baseline in DLQI and the percent change from baseline at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.
Time Frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.
To evaluate the incidence and severity of adverse events.
Time Frame: From ICF signed to end of study follow-up (at 54 weeks).
Number and percentage of participants with treatment-emergent adverse events (TEAEs), graded by severity according to CTCAE 5.0.
From ICF signed to end of study follow-up (at 54 weeks).
To evaluate the pharmacokinetic profile (including plasma concentrations and derived parameters) over time at Weeks 0, 2, 4, 8, and 12.
Time Frame: From enrollment to end of treatment at 2,4,8,12 weeks
From enrollment to end of treatment at 2,4,8,12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Newsoara Biopharma Co., Ltd.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Jianzhong Zhang, Peking University People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 20, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 29, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 20, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 7, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 14, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 17, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 17, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 14, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • HPP737-Psoriasis-301

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psoriasis

Clinical Trials on HPP737

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings